Viracta Therapeutics, Inc. (VIRX) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Micron rises as White House presses Apple to avoid Chinese memory chips
Viracta Therapeutics (VIRX) PT Lowered to $4 at RBC Capital
August 15, 2024 6:16 AM EDTRBC Capital analyst Kennen MacKay lowered the price target on Viracta Therapeutics (NASDAQ: VIRX) to $4.00 (from $6.00) while maintaining a Outperform rating.
The analyst comments "VIRX shared new NAVAL-1 data (Stage 1+2) that suggest stronger efficacy of Nana-val in 2L EBV+ PTCL (vs. 2L+,... More
